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Abstract
Pf38 is a surface protein of the malarial parasite Plasmodium falciparum. In this study, we produced and purified
recombinant Pf38 and a fusion protein composed of red fluorescent protein and Pf38 (RFP-Pf38) using a transient
expression system in the plant Nicotiana benthamiana. To our knowledge, this is the first description of the production of
recombinant Pf38. To verify the quality of the recombinant Pf38, plasma from semi-immune African donors was used to
confirm specific binding to Pf38. ELISA measurements revealed that immune responses to Pf38 in this African subset were
comparable to reactivities to AMA-1 and MSP119. Pf38 and RFP-Pf38 were successfully used to immunise mice, although
titres from these mice were low (on average 1:11.000 and 1:39.000, respectively). In immune fluorescence assays, the
purified IgG fraction from the sera of immunised mice recognised Pf38 on the surface of schizonts, gametocytes,
macrogametes and zygotes, but not sporozoites. Growth inhibition assays using aPf38 antibodies demonstrated strong
inhibition ($60%) of the growth of blood-stage P. falciparum. The development of zygotes was also effectively inhibited by
aPf38 antibodies, as determined by the zygote development assay. Collectively, these results suggest that Pf38 is an
interesting candidate for the development of a malaria vaccine.
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Introduction
Malaria continues to be a major health burden worldwide. In
2010, 216 million estimated cases and 655.000 deaths from
malaria were reported. Ninety-one percent of these malaria cases
were due to infection with P. falciparum [1]. Although increasing
knowledge about the parasite and its interaction with its two host
organisms, humans and mosquitoes, has amassed, a viable strategy
to prevent the disease has yet to be identified. Current efforts to
control malaria, including insecticide-treated mosquito nets,
spraying of long-lasting insecticides [2] and artemisinin-based
combination therapy as a first treatment [3], diminish malaria
incidence but continue to leave a high burden of this disease in
sub-Saharan areas [4]. Additionally, imperfect diagnostics and
self-medication [5] have led to inaccurate data collection and an
underestimation of malaria cases. Furthermore, resistance among
malaria vectors (e.g., resistance to pyrethroid insecticides) has been
detected in many countries in sub-Saharan Africa [6], indicating
that moderately effective measures today could become useless in
the future.
A desirable means to control malaria would be a vaccine
capable of eliciting a protective immune response, and numerous
approaches to develop such a malaria vaccine have been pursued
over the last 70 years [7,8]. It is assumed essential that such a
vaccine would not only prevent clinical symptoms but also inhibit
the transmission of the disease-causing parasites via mosquitoes to
completely eradicate the disease [9,10]. No commercially available
malaria vaccines exist to date. Although there are candidate
vaccines in clinical trials, it is unclear whether these will be
sufficiently effective at preventing disease, particularly in regard to
mid- and long-term efficacy [11–13].
In the process of searching for a candidate for a new malaria
vaccine, we became interested in Pf38 (GenBank accession
ABO41470.1), which was proposed as a potential vaccine
candidate in 2005 [14]. Pf38 is a glycosylphosphatidylinositol
(GPI)-anchored merozoite surface protein [14] that accounts for
5% of the total GPI-anchored proteins on the merozoite surface
and is concentrated in apical secretion organelles in early schizonts
[15]. Pf38 belongs to the six-cysteine family (6-cys), a conserved,
apicomplexan specific protein family characterized by cystein rich
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motives sharing a common spacing pattern of the 6 cystein
residues that form three intramolecular disufide bonds [16]. Other
well-known members of the 6-cys family are e.g. Pfs 48/45,
Pfs230, Pf12 [16].
Peptides of Pf38 were shown to have a high affinity for
erythrocytes and diminished their invasion by Plasmodium [17].
Furthermore, Pf38 is well-recognised by sera from adults from
Papua New Guinea [14] and Kenya [18] and has been identified
as one of few Plasmodium surface proteins to have a signature of
balancing selection [19,20] (i.e., polymorphisms of Pf38 are
maintained to facilitate immunoevasion by the parasite). Finally,
because Pf38 is expressed during both the asexual and sexual
stages [14], blocking Pf38 could both prevent the blood-stage
symptoms of malaria and block transmission of the disease, which
makes Pf38 an interesting potential malaria antigen. As a
production platform we used transiently transformed Nicotiana
benthamiana. Although the production of recombinant proteins in
plants is slightly unusual this system has worked well for us in the
past; it has also been used successfully for the production of other
malaria vaccine candidates [21,22]. In order to investigate the
suitability of Pf38 as a malaria vaccine, we produced Pf38 and a
fusion protein composed of red fluorescent protein and Pf38 (RFP-
Pf38). Both recombinant proteins were used for generation of
polyclonal antibodies which proved to have an inhibitory effect on
the development of the malaria parasite.
Results
Production and purification of Pf38 and RFP-Pf38
The DNA-sequences coding for Pf38 and RFP-Pf38 were
cloned into the plant expression vector pTRAkc [23]. A schematic
depiction of the expression cassette is shown in Figure 1.
Agrobacterium tumefaciens was transformed with either of the two
vectors; cultures of these transgenic A. tumefaciens were used to
transiently transform N. benthamiana. After a few days of incubation
the leaves of the transiently transformed plants were harvested.
Pf38 and RFP-Pf38 were both successfully produced in and
purified from these transiently transformed N. benthamiana leaves,
although the yield of the recombinant proteins was low. Following
purification of the proteins, including fractionated ammonium
sulphate precipitation, IMAC and anion exchange chromatogra-
phy, the yield was 4 mg/g leaf fresh weight for Pf38 and 12 mg/g
leaf fresh weight for RFP-Pf38, the total amount of Pf38 and RFP-
Pf38 purified was 550 mg and 320 mg respectively. The purity and
integrity of both recombinant proteins were analysed by SDS-
PAGE with subsequent Coomassie staining and immunoblotting
(Figure 2). The observed size of the proteins was in accordance
with the expected values at 40 kDa (Pf38) and 67 kDa (RFP-Pf38),
though some heterogeneities were observed for Pf38. These are
probably due to glycosylation as there are three potential
glycosylation sites in the sequence of Pf38 (GenBank accession
KC987075). Purified samples of Pf38 and RFP-Pf38 were not
stable when stored at 4uC (data not shown), and were therefore
stored at 280uC until further use.
Plasma reactivities of African serum samples against Pf38
Plasma from 31 semi-immune African blood donors was
assayed for reactivity against the antigens Pf38, AMA-1 and
MSP119-His using an enzyme-linked immunosorbent assay
(ELISA). Positive reactivity was defined as a reading of greater
than twofold the values obtained for the negative control samples
(European serum samples, NIS). The enzymatic immunoabsor-
bent assay revealed that 94% (corresponding to 29 out of 31
samples) of the African serum samples from semi-immune donors
reacted positively against Pf38. A high reactivity (more than
twenty fold the negative control reactivity) was found in 61% of
the samples, while 35% (11 samples) showed reactivities that were
more than one hundred-fold above the negative control reactivity
(Figure 3A). The semi-immunity of the African blood donors was
confirmed by their reactivity towards two further antigens AMA-1
and MSP119-His (Figure 3A).
The recombinant Pf38 is a His-tagged protein; to control for
human serum antibodies binding to the His-tag or to denatured
protein, two control ELISA were performed against denatured
and reduced Pf38 and against the His-tagged recombinant human
protein Trefoil factor 3 (TFF3-His). Denaturing and reducing the
protein Pf38 reduced the reactivity by more than 50% in 29 of 31
plasma samples, in more than 67% of the plasma samples, the
reactivity was reduced by more than 90%. The reactivity of the
plasma samples to the His-tagged control protein TFF3-His is
significantly lower than the reactivity to native Pf38 (p,0.0001,
Kruskal-Wallis rank sum test). Nevertheless, two samples reached
levels of more than 30% reactivity compared to Pf38, but these
two samples are both having a reactivity against the antigen Pf38
Figure 1. Pf38 and RFP-Pf38 plant expression cassette. 35SS: 35S
promoter of the Cauliflower mosaic virus with duplicated 35S enhancer
region; CHS 59 UTR: 59 untranslated region of chalcone synthase
(Petroselinum crispum); TS: Targeting signal sequence; RFP-Pf38: cDNA
encoding the fusion protein comprising a red fluorescent protein and
Pf38 of P. falciparum; Pf38: cDNA encoding protein Pf38 of P. falciparum;
His-tag: sequence coding for six histidines; KDEL: retention signal for
the endoplasmatic reticulum; NcoI/NotI: restriction sites used for
cloning; pTRAkc: vector backbone of pTRAkc.
doi:10.1371/journal.pone.0079920.g001
Figure 2. Purity and integrity of Pf38 and RFP-Pf38. Coomassie-
stained SDS-PAGE (B, D) and immunoblot (A, C) analysis of Pf38 (A, B)
and RFP-Pf38 (C, D) after purification. Detection of recombinant
proteins was performed using a rabbit aHis antiserum and an alkaline
phosphatase-labelled goat arabbit antiserum with nitroblue tetrazoli-
um/5-bromo-4-chloro-3-indolyl-phosphate solution as the substrate. M:
PageRulerTM Prestained protein ladder (Fermentas), Pf38: 1 mg of Pf38,
RFP-Pf38: 1 mg RFP-Pf38.
doi:10.1371/journal.pone.0079920.g002
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which is below two-fold the negative control and thus was not
regarded as a positive reaction to the target antigen.
Immunisation and titre determination
The immunogenicity of Pf38 and RFP-Pf38 in BALB/c mice
was evaluated using a direct ELISA. Pf38-immunised mice had an
average titre of 1:11.000 against Pf38. RFP-Pf38-immunised mice
had an average titre of 1:560.000 against RFP-Pf38, although
titres against Pf38 from these same animals were much lower, with
an average titre of 1:39.000. The sera of the three mice that were
immunised with the same antigen were pooled, and the IgGs were
purified from both pools via protein G immunoaffinity chroma-
tography. The total amount of IgG after purification was 4.9 mg
for Pf38-immunised mice and 3.7 mg for RFP-Pf38-immunised
mice.
Immunofluorescence assay (IFA)
IFAs were prepared using different lifecycle stages of P.
falciparum. Mature schizonts were used to check for the presence
of Pf38 on the surface of asexual-stage parasites. Strong
Figure 3. Plasma reactivity of a semi-immune human cohort from Ghana against Pf38 and the control proteins AMA-1, MSP119-His,
TFF3-His and denatured PF38. Plasma from 31 semi-immune African serum donors and two European control donors was assayed for reactivity
against Pf38 by ELISA. (A) Plasma reactivity is shown as the reactivity of African individual samples (G01–G31) and the European non-immune sample
(NIS) relative to a standard African Plasma Pool expressed as relative Arbitrary Units (rAU), +/2 the standard deviation. Individual plasma reactivity
towards Pf38 (black), AMA-1 (red) and MSP119-His (blue) is shown. (B): Plasma reactivities to denatured and reduced Pf38 (black bars) and TFF3-His
(checked bars) are represented as percentage +/2 the standard deviation relative to the plasma reactivity to native Pf38. The dashed line represents
the reactivity to native Pf38. Check marks at sample Identifications highlight either low (*) or no (**) reactivity of the plasma sample to Pf38. All
experiments were performed in triplicate.
doi:10.1371/journal.pone.0079920.g003
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fluorescence was observed using both aPf38 and aRFP-Pf38
murine IgGs, and this fluorescence coincided clearly with that of
control aAMA-1 antibodies (Figure 4, Figure S1). Earlier stages
(i.e. ring stage parasites, trophozoites) show weak staining (Figure
S2). Pf38 staining on asexual-stage parasites showed an equal
distribution of the protein, in accordance with earlier reports [14],
while AMA-1 staining was detected only at the apical pole of the
developing merozoites [24]. IFA staining of sexual-stage parasites,
macrogametes and zygotes produced weak signals, while the
gametocyte staining was clearly visible (Figure 4, Figure S1). All
Plasmodium lifecycle stages were also treated with a control IgG
fraction as a negative control, and no binding could be detected in
any of the stages (Figure S3). The specificity of the generated
aPf38 and aRFP-Pf38 antibodies was verified by immunoblot
analysis of a complete parasite cycle under non-reducing
conditions (Text S1, Figure S4).
Growth inhibition assay (GIA)
To evaluate the inhibitory potential of antibodies generated by
immunisation with Pf38 or RFP-Pf38 on the invasion of
Plasmodium into red blood cells, a GIA was performed on P.
falciparum 3D7A using the IgG fraction of serum collected from
immunised mice (Figure 5). aPf38, aRFP-Pf38 and murine IgG
from mice immunised with a non-malaria-related protein (negative
control) were tested at a final concentration of 4 mg/ml, while
rabbit aAMA-1 (positive control) was used at 6 mg/ml. The
negative control was used to calculate the maximal growth of the
parasite culture. The positive control demonstrated the expected
growth inhibition of 80–100%. In the first two experiments, aPf38
IgG caused an inhibition of approximately 60%, while an
inhibition of 87% was achieved in the third experiment. For the
aRFP-Pf38 IgG, a growth inhibition of approximately 10–20%
was observed for two experiments, while the third experiment
failed.
Zygote development assay (ZDA) and transmission
blocking assay (TBA)
ZDA was performed with active and heat-inactivated human
sera to investigate the ability of purified aPf38 and aRFP-Pf38
antibodies to initiate complement-mediated lysis of round forms
and thus prevent zygote formation. The ZDA (Table 1) showed a
significant inhibition equal to 76% for aRFP-Pf38 sera and 74%
for aPf38 sera using active human serum. For inactive human
serum, no inhibition was detected (Table 2). Four membrane feed
experiments were performed on mosquitoes to evaluate the
transmission-blocking ability of aPf38 and aRFP-Pf38 antibodies.
A mixture of purified gametocytes and fresh erythrocytes was
mixed with active human serum supplemented with the appro-
priate test IgG. The mixture was then fed to mosquitoes, and the
guts of these mosquitoes were observed for infection 9–11 days
later. Data obtained from the dissected/infected mosquitoes and
the counted oocysts (Table 3) demonstrated a significant trans-
mission-blocking activity only in one TBA experiment for the
aPf38 antibodies. No transmission-blocking effect has been
observed for the aRFP-Pf38 antibodies.
Discussion
Pf38 has been suggested as an interesting candidate for a
malaria vaccine [14,17]. To investigate this possibility, we
produced both Pf38 and a RFP-Pf38 fusion protein. Plants were
used for the production of recombinant Pf38 and RFP-Pf38, as
plants offer some benefits over other production systems, such as a
fast appraisal of constructs [25] and cost-effective large-scale
production [26]. Moreover, plant-derived proteins are free of
endotoxins and human pathogens [27]. While other reports on
Pf38 exist [14,15–17,18], this study is the first to report that
recombinant Pf38 can be produced and purified. Although our
yields of Pf38 and RFP-Pf38 after purification were relatively low
(4 mg and 12 mg per gram leaf fresh weight, respectively),
especially when compared to other P. falciparum proteins produced
in N. benthamiana [21,22], the amounts of Pf38 and RFP-Pf38
generated were sufficient for immunisations and screenings. The
quality of the recombinant Pf38 was assessed by ELISA using
serum samples from malaria semi-immune donors, and over
ninety percent of the tested serum samples reacted positively or
Figure 4. Immunofluorescence assay of NF54 parasites in
different stages. For IFAs, P. falciparum NF54 parasites in the schizont,
gametocyte, macrogamete and zygote stages were fixed with methanol
on the surface of a slide. aPf38: Detection was performed using the
protein G-purified aPf38 murine IgG fraction. aRFP-Pf38: Detection was
performed using the protein G-purified aRFP-Pf38 murine IgG fraction.
As a positive control, a rabbit aAMA-1 IgG fraction was used for
schizonts, and rabbit aPfs25 serum was used for the sexual stages. (a)
Visualisation of murine IgG with Alexa Fluor 488 secondary antibodies
(green), (b) visualisation of rabbit IgG with Alexa Fluor 594 secondary
antibodies (red), (c) bright light (d) overlay of pictures a, b, and c. Bar:
5 mm.
doi:10.1371/journal.pone.0079920.g004
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very positively with the native recombinant Pf38. (Figure 3A). In
contrast to this, antibodies from semi-immune donors did not react
strongly to denatured and reduced recombinant Pf38 (Figure 3B).
This suggests a near native conformation of the plant-produced
Pf38. Additionally, the presence of these antibodies in the blood-
donors that were recruited on the basis of being free from clinical
malaria infection for at least two years, might give a hint for a role
for Pf38 in protective immunity. However, the later hypothesis
needs to be confirmed in a survey comparing a population
protected against clinical malaria vs. a population living in the
same setting while not being protected.
We generated the fusion variant of Pf38 for two reasons. First,
the expression of RFP has worked well in our lab [28,29], and we
hypothesised that an attached RFP might help stabilise the
protein. Second, no prior knowledge existed regarding the
immunogenicity of Pf38. Using the Immune Epitope Database
and Analysis Resource tool for the prediction of MHC-II T-cell
epitopes [30], we found that only moderate affinities for Pf38 were
predicted. Therefore, the attachment of RFP, which has high
immunogenicity itself, could boost the immunogenic effect of Pf38.
This hypothesis proved to be true, as the titres against Pf38 were
nearly four times higher in RFP-Pf38-immunised mice (1:38.000)
versus Pf38-immunised mice (1:11.000); however, the quality of
the immune responses was also different, with the IgG fraction
purified from the serum of Pf38-immunised mice being more
effective (Figure 5; Table 3). The IFAs further confirmed that
plant-produced Pf38 was able to induce the generation of specific
aPf38 antibodies in mice, which could detect native Pf38 on P.
falciparum surfaces in different stages (Figure 4). While Pf38 has
been detected on schizonts [18], this is to our knowledge the first
study to report the detection of Pf38 on the surface of gametocytes,
macrogametes and zygotes. The IFA results also confirmed
previous transcription data suggesting that Pf38 is present on the
surface of schizonts and gametocytes [14,15]. Although it has been
predicted that Pf38 is present on the surface of sporozoites as well
[14,15], it was not possible to identify the protein on sporozoites by
IFA here (data not shown).
To evaluate the inhibitory functions of aPf38 and aRFP-PF38
antibodies, we first focused on the blood stages of the parasite. The
inhibition of erythrocyte invasion by merozoites was analysed
using a GIA, and the in vitro growth inhibition of P. falciparum
3D7A with aPf38 antibodies showed a 60% to 87% inhibition. In
comparison to aAMA-1 antibodies, which were used as a control
(demonstrating 80–100% inhibition), aPf38 antibodies showed
relatively strong inhibition; moreover, these high inhibitory values
relative to AMA-1 were obtained despite the amount of aAMA-1
antibodies being 50% greater than the amount of aPf38 antibodies
used in the assay (an adjustment that was made to compensate for
the relative small amount of serum that could be obtained from
mice). Data on a GIA using aPf38 antibodies from rabbits
obtained via a viral vectored vaccine [18] show a lower inhibition,
which might be due to the different experimental approach.
Although the titre against Pf38 from RFP-Pf38-immunised mice
was approximately four times higher than titres from Pf38-
immunised mice, growth inhibition by these antibodies was only
10–20%, suggesting that titre alone is not the deciding factor for
strong inhibition. One can speculate that native Pf38 may fold
more efficiently than a fusion Pf38 construct, resulting in
antibodies whose paratopes are better suited for recognition of
native Pf38.
As Pf38 was detected on the surface of sexual-stage P. falciparum,
the ability of aPf38 and aRFP-Pf38 antibodies to inhibit parasite
round forms and thus prevent zygote formation was assessed. Our
results (Table 1) demonstrated significant inhibitions of 76% and
Figure 5. In vitro growth inhibition of 3D7A parasites with
aPf38 antibodies. A GIA was performed with P. falciparum 3D7A
parasites and protein G-purified IgG fractions. aAMA-1: Rabbit aAMA-1
IgG fraction (positive control); aPf38: murine aPf38 IgG fraction; aRFP-
Pf38: murine aRFP-Pf38 IgG fraction. Each experiment (represented by
one bar in the graph) was performed in triplicate. Bars depicted in the
same colour indicate experiments that were performed in parallel.
Inhibition was calculated as described in the materials and methods.
doi:10.1371/journal.pone.0079920.g005
Table 1. Results from ZDAs performed in the presence of active human serum.
Experiment 1 Experiment 2 Experiment 3
IgG(a) round forms(b) [%] P-values(c) round forms(b) [%] P-values(c) round forms(b) [%] P-values(c)
Control 100612 100621 100610
RFP-Pf38 2668 0.0011 2162 0.0025 2562 0.0002
Pf38 2969 0.0016 2666 0.0035 2268 0.0004
(a)Protein G-purified IgG from mice were used at a final concentration of 1 mg/ml. Polyclonal IgG purified from mice immunised with a non-malaria-related antigen was
used as a negative control (Control). The IgG used originated from mice immunised either with the RFP-Pf38 fusionprotein or with Pf38 alone.
(b)Counts of round forms are given in percentages, and the mean number of round forms in controls was defined as 100%. Means and standard deviations were
calculated from the counts of three 0.1 ml aliquots of each sample using a hemocytometer.
(c)Student’s t-test was used to statistically analyse the difference in counts of round forms between samples supplemented either with control IgG or test IgG.
P-values below 0.05 were considered significant.
doi:10.1371/journal.pone.0079920.t001
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74% with aRFP-Pf38 and aPf38 antibodies, respectively, in the
presence of active human serum. In the presence of inactive sera,
no significant inhibition could be achieved. By using the round-
form inhibition assay with active and inactive sera, insights into the
mode of inhibition could be gained. Because active human serum
was necessary for inhibition, it is likely that activation of the
complement system, similar to that described for Pfs230 [31], is a
crucial part of the observed inhibition. As zygote formation was
strongly inhibited, it was of interest to study whether the aPf38 and
aRFP-Pf38 antibodies would also have transmission-blocking
ability. Only one out of four experiments showed a significant
inhibition of transmission by aPf38 antibodies, which was
unexpected. It can be assumed that the amount of antibodies
reaching the mosquito gut in the TBA is more variable in
comparison to the amount of antibodies used in the ZDA, as
factors such as the size of the blood meal and the individual
mosquito gut environment will influence the concentration of
active antibodies in the gut. Future experiments would benefit
from the use of greater concentrations of aPf38 antibodies in
TBAs i.e. an optimisation of immunisation strategies. Currently, it
should be noted that no significant transmission-blocking activity
was observed.
In summary, recombinant Pf38 is able to induce an immune
response in mice, and the murine antibodies generated during this
response can strongly inhibit the growth of blood-stage P.
falciparum and the formation of round forms in vitro. Furthermore
the strong reactivities of semi-immune African donors to Pf38 give
an indication of the involvement of aPf38 antibodies in protective
immunity against malaria. We agree that an effective malaria
vaccine should most likely be based on several antigens [32] or
subdomains directed to several stages of the parasite lifecycle [17];
Pf38 or a part of Pf38 could be one such subdomain of a malaria
vaccine. Unfortunately, the yields of recombinant Pf38 in plants
were low, although this problem may be alleviated by producing
only one part of Pf38 or by producing Pf38 in the context of a
larger construct consisting of various malaria-related antigens.
From the observations made in this study, we conclude that Pf38 is
Table 2. Results from ZDAs performed in the presence of inactive human serum.
Experiment 1 Experiment 2 Experiment 3
IgG(a) round forms(b) [%] P-values(c) round forms(b) [%] P-values(c) round forms(b) [%] P-values(c)
Control 100630 100621 10065
RFP-Pf38 90635 0.7183 119615 0.274 98611 0.7559
Pf38 125630 0.3169 115615 0.356 10067 0.9488
(a)Protein G-purified IgG from mice were used at a final concentration of 1 mg/ml. Polyclonal IgG purified from mice immunised with a non-malaria-related antigen was
used as a negative control (Control). The IgG used originated from mice immunised either with the RFP-Pf38 fusionprotein or with Pf38 alone.
(b)Counts of round forms are given in percentages, and the mean number of round forms in controls was defined as 100%. Means and standard deviations were
calculated from the counts of three 0.1 ml aliquots of each sample using a hemocytometer.
(c)Student’s t-test was used to statistically analyse the difference in counts of round forms between samples supplemented either with control IgG or test IgG.
P-values below 0.05 were considered significant.
doi:10.1371/journal.pone.0079920.t002
Table 3. Evaluation of transmission-blocking activity of purified mouse IgG.
Experiment IgG(a)
mean number of
oocysts (range) p-values(b)
Mosquitoes infected/
dissected
Inhibition of
transmission [%] p-values(c)
1 Control 7 (0–35) 17/20
RFP-Pf38 4 (0–33) 0.258 15/20 12 0.6948
Pf38 9 (0–35) 0.758 13/19 20 0.2733
2 Control 7 (0–28) 17/20
RFP-Pf38 7 (0–28) 0.779 16/20 6 0.4075
Pf38 1 (0–13) 0.01 9/20 47 0.0187
3 Control 2 (0–12) 13/20
RFP-Pf38 6 (0–39) 0.242 15/20 0 0.7311
Pf38 7 (0–37) 0.231 15/20 0 0.7311
4 Control 1 (0–7) 7/20
RFP-Pf38 1 (0–2) 0.947 8/20 0 .0.9999
Pf38 2 (0–19) 0.841 7/20 0 .0.9999
(a)Protein G-purified polyclonal IgG from mice were used at a final concentration of 1 mg/ml. Polyclonal IgG purified from mice immunised with a non-malaria-related
antigen was used as a negative control (Control). The antisera used originated from mice either immunised with the RFP-Pf38 fusionprotein or with Pf38 alone.
(b)A Mann-Whitney U test was used to analyse the median numbers of oocysts between groups of mosquitoes either receiving control IgG or test IgG during infection
with P. falciparum. P-values below 0.05 were considered significant.
(c)Fisher’s exact test was used to analyse the oocyst prevalence between groups of mosquitoes either receiving control IgG or test IgG during infection with P.
falciparum.
P-values below 0.05 were considered significant.
doi:10.1371/journal.pone.0079920.t003
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a promising candidate for the development of a multi-stage
malaria vaccine.
Materials and Methods
Ethics statement
The animal experiments were officially approved by the
Landesamt fu¨r Natur, Umwelt und Verbraucherschutz Nordr-
hein-Westfalen (LANUV), reference number 8.87.-
51.05.30.10.077. All animals received humane care in accordance
with the requirements of the German Tierschutzgesetz, 18 Abs. 1
and in accordance with the Guide for the Care and Use of
Laboratory Animals published by the National Institute of Health.
The human study was conducted according to the Helsinki
Declaration on Scientific Research and received approval from the
regional Committee on Human Research Publication and Ethics
(CHRPE) of The Kwame Nkrumah University of Science and
Technology. After explaining the aims and procedures of the
study, written informed consent was obtained from the partici-
pants. All study participants were clinically examined and all
pregnant or nursing mothers, as well as anaemic volunteers, were
excluded from the study.
Bacteria, plants and parasites
Agrobacterium tumefaciens strain GV3101 : : pMP90RK [GmR,
KmR, RifR] [33] and N. benthamiana plants were used for
agroinfiltration, i.e., the production of recombinant proteins by
plants. For IFA, ZDA and TBA, the parasite P. falciparum NF54
(MRA-1000, MR4, Manassas, USA) was used, while GIA were
performed using P. falciparum 3D7A (MRA-151, MR4, Manassas,
USA), a substrain of NF54 [34].
Plant expression vector design and construction
The cDNA for Pf38 was constructed based on the Pf38 cDNA
from P. falciparum (GenBank accession ABO41470.1). The DNA
sequence encoding the last 21 amino acids, which form the GPI
anchor attachment region, was omitted, and the remainder of the
gene was codon optimised for tobacco. The following short
sequence additions were made at either ends of the cDNA to
facilitate cloning: 59 GGTACCGAATTCTC-
CATGGTGGCGGCCGGAGACCTGCGTATT 39 at the 59
end of the gene, adding a NcoI and a BsaI restriction site; and 59
CGGCCGCGAGGCATAGGGATCCTCTAGATGGAGCT 39
at the 39 end of the gene, adding a NotI, BamHI and XbaI
restriction site. The final sequence (GenBank accession
KC987075) was used to produce a synthetic gene (GeneArt),
and the gene was cloned via NcoI/NotI into pTRAkc-ERH and
pTRAkc-rfp-ERH [23]. Both vectors contained the DNA
sequence for a signal peptid, a His-tag and a retention signal for
the endoplasmatic reticulum, pTRAkc-rfp-ERH contains also the
cDNA for a tetrameric red fluorescent protein (RFP) of Discosoma
spec. (Figure 1). All cloning was confirmed by sequencing.
For the silencing inhibitor, the p19 gene was amplified by PCR
from pEAQ-HT [35] using primers to introduce an NcoI site at the
start codon and a SpeI site behind the stop codon. The NcoI/SpeI-
digested PCR product was ligated into AflIII/XbaI-digested
pTRAc to produce pTRAc-p19si.
Transient transformation of N. benthamiana
All three plant expression vectors described above were
separately introduced into A. tumefaciens using a Multiporator
(Eppendorf AG), according to the manufacturer’s instructions.
A. tumefaciens cells containing one of the three plasmids (pTRAc-
p19si, pTRAkc-Pf38-ERH or pTRAkc-RFP-Pf38-ERH) were
cultivated in YEB medium [36] containing 50 mg/ml carbenicillin,
25 mg/ml kanamycin and 25 mg/ml rifampicin. One day before
the infiltration, the cultures were pre-induced by the addition of 2-
(N-morpholino)ethanesulfonic acid from a stock solution (pH 5.6),
glucose (to a final concentration of 10 mM) and acetosyringone
(20 mM final concentration). On the day of the infiltration, the
cultures were prepared by dilution to an OD600 = 2 using water.
The diluted cultures were then mixed in equal parts with 26
infiltration medium (10% (w/v) sucrose, 0.398% (w/v) glucose,
0.01% (w/v) Ferty2 Mega (Planta Du¨ngemittel GmbH, pH 5.6)
and acetosyringone (200 mM final concentration) and incubated
for 2 hours at room temperature. The final infiltration suspension
contained 80% (v/v) of the induced agrobacteria containing
pTRAkc-Pf38-ERH (or pTRAkc-rfp-Pf38-ERH) and 20% (v/v) of
the induced agrobacteria containing pTRAc-p19si. Plants used for
agroinfiltration were grown in a greenhouse under a 16 hours
natural daylight photoperiod and a 25uC/day and 22uC/night
temperature regimen. The plants were approximately eight weeks
old at the time of infiltration.
Whole N. benthamiana plants with roots in rock wool were
immersed upside down into the infiltration suspension and were
vacuum-infiltrated [23]. After the infiltration, the plants were
cultivated for 4–10 days at 25uC with 16 hours of light per day
(110 mE) and regular watering. Only leaves were harvested and
stored at 220uC until later use.
Purification of Pf38 and RFP-Pf38
For the purification of Pf38, the total soluble protein from
infiltrated tobacco leaves was extracted by macerating a 1:3 (w/v)
ratio of plant material and ice cold extraction buffer (100 mM
Tris-HCl pH 8, 100 mM NaCl, 10 mM sodium disulphite,
10 mM EDTA, 2 mM DTT, 10 mM benzamidine, 5 mM
aminocaproic acid, 5 mM imidazole) in a blender. The resulting
green slurry was first filtered through a double layer of Miracloth
and then mixed with solid ammonium sulphate to 30% saturation.
After centrifugation at 40.000 g (4uC, 20 minutes), the superna-
tant was separated from the pellet and then mixed with
ammonium sulphate to a saturation of 60%. The sample was
then centrifuged as described above. The supernatant was
discarded, and the pellet was redissolved in NTA-buffer (50 mM
Tris-HCl pH 8, 500 mM NaCl) containing 5 mM imidazole and
applied to a Ni-NTA matrix (Macherey-Nagel). The column was
washed with 40 column volumes (cv) washing buffer (NTA-buffer
containing 10 mM imidazole). Elution of the recombinant
proteins from the Ni-NTA was achieved with elution buffer
(NTA-buffer containing 200 mM imidazole). The elution fractions
were tested via SDS-PAGE and immunoblot for the presence of
Pf38, and the fractions that contained the recombinant proteins
were combined. A buffer exchange into AEX-buffer (20 mM
sodium phosphate pH 6.9) was performed using PD10-columns
(GE Healthcare). Anion exchange chromatography was carried
out using DEAE sepharose fast flow (GE Healthcare Bio-Sciences
AB). The sample was loaded onto the column, and the
flowthrough was collected. The column was then washed with 4
cv AEX buffer containing 20 mM NaCl, and the flowthrough and
the wash fraction were combined, buffer exchanged into PBS and
subsequently concentrated using centrifugal concentrators (Vivas-
pin 6, MWCO 10 kDa; Sartorius Stedim Biotech GmbH). Until
further use, the purified proteins were stored at280uC. RFP-PF38
was purified in the same way, except that no imidazole was added
to the extraction buffer or NTA-buffer.
Analysis of the purity and integrity of the purified proteins was
performed via SDS-PAGE with subsequent Coomassie staining
and immunoblotting. This was done as described before [37], and
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Pf38 was detected via the His-tag attached to the protein using a
rabbit aHis antiserum (GenScript). For the secondary antibody, an
alkaline phosphatase-labelled goat arabbit antiserum (Jackson
ImmunoResearch) was used, and nitroblue tetrazolium/5-bromo-
4-chloro-3-indolyl-phosphate solution was utilised as the substrate.
Plasma reactivities of African serum samples against Pf38
From 31 semi-immune adults from the region of Kumasi,
Ghana, 7.5 ml of blood was withdrawn into heparinised blood
tubes. Blood donors were selected on the basis of living in this
holoendemic region and being free from clinical malaria infection
for at least two years. Plasma was separated and frozen until it was
used in an ELISA. As a negative control, plasma from two
European donors, who had never experienced malarial infection,
was withdrawn and treated in the same way.
To investigate naturally occurring reactivity against the Pf38
antigen, an ELISA was performed according to standardised
procedures with small modifications [38,39]. Besides Pf38, two
positive controls, AMA-1 (diversity covering PfAMA-1 produced
in Pichia pastoris) [40] and Msp119-His (3D7; produced in HEK293)
and an unrelated His-tagged protein, the human Trefoil factor 3
(TFF3-His, produced in Hek293) as a negative control were tested
in the same ELISA. In short, 50 ng of antigen at a concentration
of 1 mg/ml was coated overnight on 96-well high-binding EIA
plates in coating buffer (0.1 M sodium carbonate). To prevent
unspecific binding, wells were blocked with PBS containing 2%
(w/v) BSA. Human plasma samples were added at serial dilutions.
As a positive control, a pool of plasma from semi-immune adults
was also prepared and added at serial dilutions. Human IgGs were
detected via an alkaline phosphate-conjugated goat ahuman IgG
(Jackson ImmunoResearch) and subsequent hydrolysation of
pNPP. The absorbance was measured at 405 nm, and the data
were analysed using the R language for statistical computing v2.13
[41].
In order to compare the reactivity of human antibodies from
semi-immune blood donors to native and denatured Pf38, an
ELISA was performed on native Pf38 and reduced and denatured
Pf38. Denaturing of the antigen was performed in 4 M Urea and
10 mM DTT at 56uC for 30 min at an antigen concentration of
10 mg/ml. Subsequently, the denatured antigen was coated on
EIA plates in a coating buffer (0.1 M sodium carbonate) at a
concentration of 1 mg/ml and the ELISA was then performed as
described above.
Immunisation of mice and collection of sera
Groups of three BALB/c mice, between 6 and 8 weeks of age
(Taconic), were immunised intraperitoneally with 17 mg Pf38 or
RFP-Pf38 emulsified in adjuvant Gerbu MM (Gerbu Biotechnik
GmbH). Another group of four mice was immunised with a non-
malaria-related antigen emulsified in Gerbu MM as a negative
control. The primary immunisation contained 40 ml Gerbu MM,
with the three subsequent boosts containing 20 ml Gerbu MM
each. The immunisations were performed every two weeks. Blood
from the tail veins of the mice was collected at the same time that
the immunisations were performed to check for titre development.
Fourteen days after the last immunisation, the mice were
narcotised, and blood was collected by cardiocentesis. After a
20 minutes incubation at RT, the blood was centrifuged (1000 g
for 10 minutes at 4uC), and the serum was separated from the
blood cells, mixed with 0.05% (w/v) sodium azide and kept at 4uC
until further use.
Determination of titres of murine aPf38 and aRFP-Pf38
The titers were determined with a standard direct ELISA.
100 ng Pf38 and RFP-Pf38/well were coated in PBS. As primary
antibodies serial diluted mouse serum was used at a dilution range
of 1:500–1:1.024.000. The secondary antibody was goat amouse
IgG (Fcc) labelled with horseradish peroxidase (Jackson Immu-
noResearch). As substrate 2, 29-azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid) (Roche) with the appropriate buffer was used
according to the manufacturers manual and absorbance was read
at 405 nm after 30 minutes. Titres were determined as the dilution
that gave the double value of the background (pre-immune serum).
Preparation of mouse sera
Total IgG was purified from pooled sera obtained from
immunised mice or control mice using a protein G-Sepharose
column (GE Healthcare) according to the manufacturer’s instruc-
tions. The serum samples, after a 10-fold dilution with binding
buffer (50 mM acetate buffer, pH 5.0), were loaded onto a protein
G-Sepharose column pre-equilibrated with binding buffer. The
column was washed with 10 cv of binding buffer. Bound IgG was
eluted with 100 mM glycine-HCl (pH 2.7), and the protein
concentration was determined by Bradford assay. The complete
eluent was filter-sterilised and concentrated to 8 mg/ml, and the
buffer was exchanged to RPMI 1640 using a 30 kDa cutoff in
AmiconUltra-15 tubes (Millipore). Finally, the purified IgG
fraction was stored at 4uC until further use.
IFA
The cultivation of parasite asexual and sexual stages and
indirect IFA were performed in the main as described previously
[42,43]. For IFA, parasite preparations were air-dried on 8-well
diagnostic slides and fixed with 280uC methanol for 10 minutes.
To block nonspecific binding and to permeabilise membranes,
fixed cells were incubated in blocking solution (0.5% (w/v) BSA,
0.01% (w/v) saponin, 1% (v/v) neutral goat serum in PBS) for
30 minutes at room temperature. The cells were then incubated
with either the total IgG fraction derived from Pf38-immunised
mice or RFP-Pf38-immunised mice diluted 1/50 in blocking
solution without goat serum at 37uC for 1 hour. For visual
identification of different P. falciparum life cycle stages, specific
rabbit-derived antibodies were used. For the visualisation of
schizonts, rabbit aAMA-1 (BG98 standard, kindly provided by
BPRC, Rijswijk, The Netherlands) was used; for gametocytes,
macrogametes and zygotes, rabbit aPfs25 (MRA-38, MR4,
Manassas, USA) was used. Visualisation of primary antibodies
was achieved by subsequent incubation of cells with fluorescence-
conjugated goat amouse (Alexa Fluor 488) and goat arabbit (Alexa
Fluor 594) antibodies (Invitrogen). If no labelling of parasites using
rabbit antibodies was performed, cells were counterstained with
0.05% (w/v) Evans Blue in PBS. Finally, cells were mounted with
the anti-fading solution AF2 (Citifluor Ltd.), and the slides were
sealed with nail varnish. The examination of labelled cells and
image scans were performed using a Leica SP5 confocal
microscope (Leica).
GIA
GIAs were performed as described previously [40]. Briefly,
protein G-purified IgG fractions (4 mg/ml final concentration),
positive control rabbit aAMA-1 (6 mg/ml final concentration),
synchronised P. falciparum schizonts and culture medium were
applied to half-area 96-well tissue culture plates in a total volume
of 50 ml/well. Each sample was tested in triplicate, and the
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experiment was repeated twice. After an incubation of 40–
42 hours, the parasitemia levels were determined using a parasite
lactate dehydrogenase assay. The percent inhibition of parasite
invasion was calculated as described previously [40].
ZDA
The ZDA used here was based on a previous publication [44].
The ability of mouse aPf38/aRFP-Pf38 antibodies to initiate
complement-mediated lysis of round forms and thus prevent
zygote formation was analysed using the round-form inhibition
assay. P. falciparum cultures containing mature stage V gametocytes
showing substantial exflagellation were aliquoted and centrifuged.
Cells were resuspended either in active human A+-serum or heat-
inactivated A+-serum supplemented with the respective test IgG.
Gametogenesis was induced by the addition of 0.1 mM xanthure-
nic acid and incubation at room temperature. Samples were
incubated overnight. Macrogametes and zygotes were visualised
by incubating cells with mouse aPfs25 antibodies, followed by
labelling with Alexa Fluor 488-conjugated goat amouse antibodies
(Invitrogen). The counting of round forms was performed using a
hemocytometer and a ZEISS Axiolab fluorescence microscope
(Zeiss).
TBA
To assess the ability of mouse aPf38/aRFP-Pf38 antibodies to
block the transmission of P. falciparum from the human to the
mosquito, membrane feeding assays were performed [45]. Briefly,
mature stage V gametocytes were first purified by Percoll density
gradient centrifugation from cultures showing substantial exflag-
ellation [46] and then mixed with an equal amount of fresh A+-
erythrocytes. Cells were then mixed with an equal amount of
active human A+-serum supplemented with the respective test IgG
and directly fed to gentamicin-treated A. stephensi mosquitoes
through a thin layer of parafilm stretched across the bottom of a
glass feeder heated to 38uC [47]. The mosquitoes were allowed to
feed for 20 minutes and were subsequently kept in a secured
insectary at 80% humidity and 26uC. To measure the infectivity of
the different samples, 20 midguts of blood-fed mosquitoes were
dissected 9–11 days after the infection and stained with 0.2% (v/v)
mercurochrome in PBS to facilitate counting of oocysts. A Mann-
Whitney U test was used to statistically analyse the median
numbers of oocysts between groups of mosquitoes either receiving
neutral mouse serum or test sera during infection with P. falciparum.
Additionally, the oocyst prevalence between groups of mosquitoes
either receiving control IgG or test IgG during infection with P.
falciparum was statistically analysed using Fisher’s exact test [48].
Supporting Information
Figure S1 Immunofluorescence assay of NF54 parasites
in different sexual stages. For IFAs, P. falciparum NF54
parasites in the gametocyte (A), macrogamete (B) and zygote (C)
stages were fixed with methanol on the surface of a slide. aPf38:
Detection was performed using the protein G-purified aPf38
murine IgG fraction. aRFP-Pf38: Detection was performed using
the protein G-purified aRFP-Pf38 murine IgG fraction. As a
positive control rabbit aPfs25 serum was used. (a) Visualisation of
murine IgG with Alexa Fluor 488 secondary antibodies (green), (b)
visualisation of rabbit IgG with Alexa Fluor 594 secondary
antibodies (red), (c) bright light (d) overlay of pictures a, b, and c.
Bar: 5 mm.
(TIF)
Figure S2 Immunofluorescence assay of NF54 parasites
in ring stage and trophozoite stage. For IFAs, P. falciparum
NF54 parasites in ring stage (A) and trophozoite stage (B) were
fixed with methanol on the surface of a slide. aPf38: Detection was
performed using the protein G-purified aPf38 murine IgG
fraction. aRFP-Pf38: Detection was performed using the protein
G-purified aRFP-Pf38 murine IgG fraction. NMS: Detection was
performed using the protein G-purified murine IgG fraction of
neutral mouse serum. As a positive control, a rabbit aAMA-1 IgG
fraction was used. (a) Nuclei were stained with Hoechst 33342. (b)
Visualisation of murine IgG with Alexa Fluor 488 secondary
antibodies (green), (c) visualisation of rabbit IgG with Alexa Fluor
594 secondary antibodies (red), (d) bright light (e) overlay of
pictures a, b, c and d. Bar: 5 mm.
(TIF)
Figure S3 Negative controls for Immunofluorescence
assays depicted in Figure 4 and Figure S1. For IFAs, P.
falciparum NF54 parasites in the schizont, gametocyte, macroga-
mete and zygote stages were fixed with methanol on the surface of
a slide. Detection was performed using the protein G-purified
murine IgG fraction of neutral mouse serum. As a positive control,
a rabbit aAMA-1 IgG fraction was used for schizonts, and rabbit
aPfs25 serum was used for the sexual stages. (a) Visualisation of
murine IgG with Alexa Fluor 488 secondary antibodies (green), (b)
visualisation of rabbit IgG with Alexa Fluor 594 secondary
antibodies (red), (c) bright light (d) overlay of pictures a, b, and c.
Bar: 5 mm.
(TIF)
Figure S4 Immunoblot to prove specificity of generated
aPf38 sera. Parasite preparations and plant produced Pf38 were
run on SDS-PAGE gel and subsequently blotted. Detection of
Pf38 was performed using murine aPf38 IgG (A) or murine aRFP-
Pf38 IgG (B) and an alkaline phosphatase-labelled goat amouse
antiserum with nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl-
phosphate solution as the substrate. For all asexual stages 4.56106
parasites were used, while the gametocyte preparation contained
56105 gametocytes. 1: Asexual parasites 12 h after invasion 2:
Asexual parasites 24 h after invasion 3: Asexual parasites 36 h
after invasion 4: Asexual parasites 48 h after invasion 5: plant
produced Pf38 (600 ng) 6: gametocyte preparation M: PageR-
ulerTM Prestained protein ladder (Fermentas).
(TIF)
Text S1 Preparation and results of immunoblot depict-
ed in Figure S4.
(DOCX)
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